Amerise Biosciences Exempt from Annual Secretarial Compliance Filing

Amerise Biosciences Ltd has confirmed its paid-up equity capital is ₹6.61 crore and its net worth is below ₹25 crore. This information is central to its exemption from filing an Annual Secretarial Compliance Report.

Key Details

Amerise Biosciences Limited has notified exchanges it is exempt from submitting its Annual Secretarial Compliance Report for the fiscal year ending March 31, 2026. The company secured this exemption under Regulation 15(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This relief applies because the company's paid-up equity capital remains below ₹10 Crore and its net worth is under ₹25 Crore.

Why It Matters

This exemption simplifies regulatory duties for Amerise Biosciences, cutting down administrative and compliance costs tied to preparing and filing the detailed secretarial report. It aligns with regulatory goals to lighten the compliance load for smaller listed companies meeting specific financial benchmarks.

Company Background

Amerise Biosciences Ltd, previously named Amradeep Industries Limited, was incorporated in 1984. Its early operations involved manufacturing construction and agricultural equipment before shifting focus to commodity and castor seed trading. Since fiscal year 2024-25, the company has been largely inactive in its business operations due to a financial crisis, with income primarily derived from non-operational sources like interest.

Impact on Operations

Shareholders can expect a reduced regulatory compliance load for the company. Amerise Biosciences will also avoid the costs and effort associated with an external secretarial audit for this specific reporting. This change marginally improves operational efficiency by removing one compliance obligation.

Associated Risks

No specific risks directly tied to this exemption announcement were identified in the filing or related searches. The company's primary risks stem from its dormant business status.

Industry Comparisons

While numerous small-cap biotechnology and pharmaceutical firms operate in India, direct comparisons for this particular exemption are limited. However, companies like Hester Biosciences Ltd, Zenotech Laboratories Ltd, and Genesis IBRC India Ltd are small-cap entities within the broader biotech sector. If they meet similar financial thresholds, they may also qualify for such exemptions from specific corporate governance compliance rules.

Financial Metrics

For fiscal years 2023-24 through 2025-26, the company's paid-up equity capital remained at ₹6.61 crore. Its net worth was ₹5.40 crore in FY 2023-24, ₹5.31 crore in FY 2024-25, and ₹5.37 crore in FY 2025-26. The exemption thresholds require paid-up capital not to exceed ₹10 Crore and net worth to stay below ₹25 Crore.

Future Monitoring

Investors should monitor any future changes in Amerise Biosciences' paid-up capital or net worth, as these could impact its eligibility for exemptions. It will also be important to observe if the company resumes active business operations or undergoes restructuring. Tracking future compliance filings will help ensure continued adherence to SEBI regulations.